secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2025-04-24T23:59:59+00:00
Accession:  0000105770-25-000031
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma CFO Birkett to retire; Campbell named Chief Proprietary Segment Officer
--------------------------------------------------------------------------------

- CFO Bernard Birkett informed West of intention to retire; search for successor initiated; will remain until transition and then advisory role through Dec 31, 2025.
- Shane Campbell appointed SVP, Chief Proprietary Segment Officer effective May 5, 2025; previously at Carlisle Companies and DuPont.
- Campbell receives $600K base salary, 75% target bonus (2025 prorated), $1M LTI award (50% PSUs, 25% options, 25% RSUs), $400K sign-on RSU (4-year vest), and $100K sign-on cash bonus.
- Birkett joined West in June 2018 and served as CFO, also as CFO & COO from 2022 to April 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577025000031/0000105770-25-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577025000031/wst-20250422.htm
  HTML page:      https://secwatch.observer/filing/0000105770-25-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer